NO944370L - Gamma-aminosyre- og L-glutaminsyreanaloger for behandling av anfall - Google Patents

Gamma-aminosyre- og L-glutaminsyreanaloger for behandling av anfall

Info

Publication number: NO944370L
Authority: NO; Norway
Prior art keywords: treatment; seizures; gamma; amino acid; compound
Prior art date: 1992-05-20

Application number

NO944370A

Other languages

English (en)

Norwegian (no)

Other versions

NO944370D0 (no

Inventor

Richard B Silverman

Ryszard Andruszkiewicz

Po-Wai Yuen

Denis Martin Sobieray

Lloyd Charles Franklin

Mark Alan Schwindt

Original Assignee

Univ Northwestern

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-05-20

Filing date

1994-11-16

Publication date

1994-11-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25388336&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO944370(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-11-16 Application filed by Univ Northwestern filed Critical Univ Northwestern

1994-11-16 Publication of NO944370D0 publication Critical patent/NO944370D0/no

1994-11-21 Publication of NO944370L publication Critical patent/NO944370L/no

Links

206010010904 Convulsion Diseases 0.000 title 1
125000003338 L-glutaminyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 title 1
229940024606 amino acid Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
125000004432 carbon atom Chemical group C* 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
206010015037 epilepsy Diseases 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C247/00—Compounds containing azido groups
- C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
- C07C247/12—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Steroid Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

NO944370A 1992-05-20 1994-11-16 Gamma-aminosyre- og L-glutaminsyreanaloger for behandling av anfall NO944370L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US88608092A	1992-05-20	1992-05-20
PCT/US1993/004680 WO1993023383A1 (fr)	1992-05-20	1993-05-18	Analogues de gaba et d'acide l-glutamique pour le traitement de maladies du systeme nerveux central

Publications (2)

Publication Number	Publication Date
NO944370D0 NO944370D0 (no)	1994-11-16
NO944370L true NO944370L (no)	1994-11-21

Family

ID=25388336

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO944370A NO944370L (no)	1992-05-20	1994-11-16	Gamma-aminosyre- og L-glutaminsyreanaloger for behandling av anfall

Country Status (22)

Country	Link
EP (1)	EP0641330B1 (fr)
JP (2)	JP3856816B2 (fr)
KR (1)	KR950701625A (fr)
AT (1)	ATE207052T1 (fr)
AU (1)	AU677008B2 (fr)
CA (1)	CA2134674C (fr)
CZ (1)	CZ286106B6 (fr)
DE (2)	DE122004000039I2 (fr)
DK (1)	DK0641330T3 (fr)
ES (1)	ES2165857T3 (fr)
FI (1)	FI945426A0 (fr)
HK (1)	HK1011022A1 (fr)
HU (2)	HU222339B1 (fr)
LU (1)	LU91112I2 (fr)
NL (1)	NL300164I2 (fr)
NO (1)	NO944370L (fr)
NZ (1)	NZ253459A (fr)
PT (1)	PT641330E (fr)
RU (2)	RU94046105A (fr)
SG (1)	SG48288A1 (fr)
SK (1)	SK283281B6 (fr)
WO (1)	WO1993023383A1 (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL113052A0 (en) *	1994-03-23	1995-06-29	Rhone Poulenc Rorer Sa	Recombinant viruses, their preparation and their use in gene therapy
HU0102040D0 (en) *	1994-07-27	2001-07-30	Warner Lambert Co	Purified gabapentine binding protein
US5792796A (en) *	1994-07-27	1998-08-11	Warner-Lambert Company	Methods for treating anxiety and panic
US5616793A (en) *	1995-06-02	1997-04-01	Warner-Lambert Company	Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) *	1995-06-07	1997-06-10	Warner-Lambert Company	Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US6372792B1 (en) *	1996-04-26	2002-04-16	Guy Chouinard	Method for treating anxiety, anxiety disorders and insomnia
ATE241351T1 (de) *	1996-07-24	2003-06-15	Warner Lambert Co	Isobutylgaba und dessen derivate zur schmerzbehandlung
AU733896B2 (en) *	1996-10-23	2001-05-31	Warner-Lambert Company	Substituted gamma aminobutyric acids as pharmaceutical agents
AU8668598A (en)	1997-08-20	1999-03-08	University Of Oklahoma, The	Gaba analogs to prevent and treat gastrointestinal damage
CA2296336C (fr)	1997-09-08	2004-04-20	Warner-Lambert Company	Compositions analgesiques comprenant des composes anticonvulsivants et leur mode d'utilisation
HU228771B1 (en) *	1998-05-15	2013-05-28	Warner Lambert Co	Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
KR100697734B1 (ko) *	1998-10-16	2007-03-22	워너-램버트 캄파니 엘엘씨	조증 및 양극성 장애 치료용 제약 조성물
AU1602100A (en)	1998-11-25	2000-06-13	Warner-Lambert Company	Improved gamma amino butyric acid analogs
CA2362026A1 (fr) *	1999-04-08	2000-10-19	Warner-Lambert Company	Methode de traitement pour l'incontinence
US6992109B1 (en) *	1999-04-08	2006-01-31	Segal Catherine A	Method for the treatment of incontinence
US7164034B2 (en)	1999-06-10	2007-01-16	Pfizer Inc.	Alpha2delta ligands for fibromyalgia and other disorders
DK1192125T3 (da) *	1999-06-10	2009-02-16	Warner Lambert Co	Mono-substituerede 3-propyl-gamma-aminosmörsyrer
US6642398B2 (en)	1999-06-10	2003-11-04	Warner-Lambert Company	Mono-and disubstituted 3-propyl gamma-aminobutyric acids
AU2002213422A1 (en)	2000-09-13	2002-03-26	Georgetown University	Synthesis of 2-hydroxymethylglutamic acid and congeners thereof
AU2002211863A1 (en)	2000-10-06	2002-04-15	Xenoport, Inc.	Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
WO2002032376A2 (fr)	2000-10-06	2002-04-25	Xenoport, Inc.	Conjugues d'acides biliaires permettant de fournir des concentrations systemiques regulieres de medicaments
US6462084B1 (en) *	2001-05-14	2002-10-08	Brookhaven Science Associates, Llc	Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
US6818787B2 (en)	2001-06-11	2004-11-16	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en)	2005-04-06	2011-11-01	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
JP4216713B2 (ja)	2001-06-11	2009-01-28	ゼノポート，インコーポレイティド	Ｇａｂａ類似体のプロドラッグ、組成物およびその使用
US7186855B2 (en)	2001-06-11	2007-03-06	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
WO2002100344A2 (fr)	2001-06-11	2002-12-19	Xenoport, Inc.	Conjugues d'amino acides permettant d'obtenir des concentrations systemiques soutenues d'analogues du gaba
US6927036B2 (en)	2002-02-19	2005-08-09	Xero Port, Inc.	Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US7026351B2 (en)	2002-03-20	2006-04-11	Xenoport, Inc.	Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof
US20030225149A1 (en) *	2002-04-30	2003-12-04	Blazecka Peter G.	Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids
US7183259B2 (en)	2002-05-17	2007-02-27	Xenoport	Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US7419981B2 (en)	2002-08-15	2008-09-02	Pfizer Inc.	Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7071339B2 (en)	2002-08-29	2006-07-04	Warner Lambert Company Llc	Process for preparing functionalized γ-butyrolactones from mucohalic acid
US7060727B2 (en)	2002-12-11	2006-06-13	Xenoport, Inc.	Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
NZ567457A (en)	2002-12-13	2009-08-28	Warner Lambert Co	Alpha-2-delta ligand to treat lower urinary tract symptoms
CA2451267A1 (fr)	2002-12-13	2004-06-13	Warner-Lambert Company Llc	Utilisations pharmaceutiques de ligands alpha2delta
WO2004054566A1 (fr)	2002-12-13	2004-07-01	Warner-Lambert Company Llc	Derives de pregabalin pour le traitement de la fibromyalgie et d'autres troubles
MXPA06002731A (es)	2003-09-11	2006-06-05	Xenoport Inc	Tratamiento y/o prevencion de incontinencia urinaria utilizando profarmacos de analogos de gaba.
CN1849153A (zh)	2003-09-12	2006-10-18	辉瑞大药厂	含有α－2－δ配体和5－羟色胺/去甲肾上腺素重摄取抑制剂的组合物
US8114909B2 (en)	2003-09-17	2012-02-14	Xenoport, Inc.	Treating or preventing restless legs syndrome using prodrugs of GABA analogs
RU2377234C2 (ru) *	2003-09-17	2009-12-27	Ксенопорт, Инк.	Лечение или предупреждение синдрома беспокойных ног с использованием пролекарств аналогов гамк
SI1677767T1 (sl)	2003-10-14	2011-11-30	Xenoport Inc	Kristalinična oblika analoga gama-aminomaslene kisline
US20050176680A1 (en)	2003-12-11	2005-08-11	Sepracor, Inc.	Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US8795725B2 (en)	2004-11-04	2014-08-05	Xenoport, Inc.	GABA analog prodrug sustained release oral dosage forms
EP1820502A1 (fr)	2006-02-10	2007-08-22	Laboratorios Del Dr. Esteve, S.A.	Combinaisons de principes actifs comprenant de dérivés d' azolylcarbinol
UA94979C2 (uk)	2006-12-22	2011-06-25	Рекордати Айеленд Лимитед	КОМБІНОВАНА ТЕРАПІЯ ПОРУШЕНЬ НИЖНІХ СЕЧОВИВІДНИХ ШЛЯХІВ ЛІГАНДАМИ α2δ І НПЗП
CA2710152A1 (fr) *	2007-12-26	2009-07-02	Generics (Uk) Limited	Procedes de preparation de la pregabaline
JP5563483B2 (ja)	2008-01-25	2014-07-30	ゼノポート，インコーポレイティド	アシロキシアルキルカルバメートプロドラッグの合成に使用されるアシロキシアルキルチオカーボネートの鏡像異性的な分解
WO2009094563A2 (fr)	2008-01-25	2009-07-30	Xenoport, Inc.	Forme cristalline d'un promédicament acide (3s)-aminométhyl-5-méthyl-hexanoïque et ses procédés d'utilisation
US7868043B2 (en)	2008-01-25	2011-01-11	Xenoport, Inc.	Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
EP2110372A1 (fr)	2008-04-16	2009-10-21	Chemo Ibérica, S.A.	Intermédiaires pour la préparation de prégabaline et leur procédé de préparation
EP2116539A1 (fr)	2008-04-25	2009-11-11	Laboratorios Del. Dr. Esteve, S.A.	1-aryl-3-aminoalkoxy-pyrazoles en tant que ligands améliorant les effets analgésiques des opioïdes et réduisant leur dépendance
EP2123626A1 (fr)	2008-05-21	2009-11-25	Laboratorios del Dr. Esteve S.A.	Co-cristaux de duloxétine et générateurs de co-cristaux pour le traitement de la douleur
CA2740087C (fr)	2008-10-08	2019-07-23	Kyphia Pharmaceuticals, Inc.	Conjugues gaba et procedes d'utilisation de ceux-ci
ES2362913B1 (es)	2009-12-24	2012-05-24	Moehs Iberica S.L.	Nuevo método para la preparación de (s)-pregabalina.
EP2353598A1 (fr)	2010-02-04	2011-08-10	Laboratorios Del. Dr. Esteve, S.A.	Ligands sigma pour utilisation dans la prévention et/ou le traitement de la douleur post-opératoire
EP2353591A1 (fr)	2010-02-04	2011-08-10	Laboratorios Del. Dr. Esteve, S.A.	Ligands sigma pour la potentialisation de l'effet analgésique d'opioïdes et d'opiacés dans la douleur post-opératoire et en atténuant la dépendance
CN102884053B (zh)	2010-03-18	2016-03-02	第一三共株式会社	环丙烷甲酸衍生物
EP2548871B1 (fr)	2010-03-18	2017-07-19	Daiichi Sankyo Company, Limited	Dérivé d'imidazole substitué par cycloalkyle
EP2383255A1 (fr)	2010-04-28	2011-11-02	Lacer, S.A.	Nouveaux composés, synthèse et utilisation dans le traitement de la douleur
EP2388005A1 (fr)	2010-05-21	2011-11-23	Laboratorios Del. Dr. Esteve, S.A.	Ligands sigma pour la prévention et/ou le traitement du vomissement induit par la chimiothérapie ou la radiothérapie
AU2011283462B9 (en)	2010-07-30	2014-09-18	Toray Industries, Inc.	Therapeutic agent or prophylactic agent for neuropathic pain
EP2415460A1 (fr)	2010-08-03	2012-02-08	ratiopharm GmbH	Formulations pour l'administration orale de prégabaline
EP2415471A1 (fr)	2010-08-03	2012-02-08	Laboratorios Del. Dr. Esteve, S.A.	Utilisation de ligands sigma dans l'hyperalgie induite par opioïdes
US8212072B2 (en)	2010-08-13	2012-07-03	Divi's Laboratories, Ltd.	Process for the preparation of pregabalin
EP2524694A1 (fr)	2011-05-19	2012-11-21	Laboratorios Del. Dr. Esteve, S.A.	Utilisation de ligands sigma dans la douleur liée au diabète de type 2
EP2527319A1 (fr)	2011-05-24	2012-11-28	Laboratorios Del. Dr. Esteve, S.A.	Formes cristallines de prégabaline et co-formateurs pour le traitement de la douleur
WO2013100873A1 (fr)	2011-12-19	2013-07-04	Mahmut Bilgic	Formulation pharmaceutique de prégabaline (taille de particules 300-2500 micromètres)
ES2423254B1 (es)	2012-02-15	2014-03-26	Laboratec, S.L.	Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis
US9066853B2 (en)	2013-01-15	2015-06-30	Warsaw Orthopedic, Inc.	Clonidine compounds in a biodegradable fiber
WO2014117176A1 (fr)	2013-01-28	2014-07-31	Lopez Hector L	Procédés d'amélioration de la tolérance à β-alanine, de sa pharmacodynamie et de son efficacité et son utilisation
TW201607538A (zh)	2013-12-17	2016-03-01	以斯提夫博士實驗室股份有限公司	血清素－去甲腎上腺素再攝取抑制劑（ＳＮＲＩＳ）和σ受體配體組合物
WO2015091505A1 (fr)	2013-12-17	2015-06-25	Laboratorios Del Dr. Esteve, S.A.	Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma
WO2016075082A1 (fr)	2014-11-10	2016-05-19	Sandoz Ag	Amination réductrice stéréosélective d'aldéhydes alpha-chiraux au moyen d'ω-transaminases pour la synthèse de précurseurs de la prégabaline et du brivaracétam
EP4227293A3 (fr)	2018-05-14	2023-10-04	Xgene Pharmaceutical Inc	Formes cristallines de conjugués médicament-carbamate de 1-(acyloxy)-alkyle de naproxène et de prégabaline
DE202018105573U1 (de)	2018-09-27	2018-10-19	Laboratec	Pharmazeutische Zusammensetzung zur Behandlung der Harninkontinenz und Enuresis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS4840460B1 (fr) *	1969-02-05	1973-11-30
US4173541A (en) *	1978-06-05	1979-11-06	Cincinnati Milacron Chemicals Inc.	Polynuclear hindered phenols and stabilized organic materials containing the phenols
US4322440A (en) *	1980-06-25	1982-03-30	New York University	Anticonvulsive compositions and method of treating convulsive disorders
US4479005A (en) *	1982-12-16	1984-10-23	The Dow Chemical Company	Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids
US4771038A (en) *	1986-01-21	1988-09-13	Ici Americas Inc.	Hydroxamic acids
US4814342A (en) *	1986-10-31	1989-03-21	Pfizer Inc.	Nor-statine and nor-cyclostatine polypeptides
KR930003864B1 (ko) *	1990-10-19	1993-05-14	한국과학기술연구원	d-2-(6-메톡시-2-나프틸)-프로피온산의 제조방법
AU9137091A (en) *	1990-11-27	1992-06-25	Northwestern University	Gaba and l-glutamic acid analogs for antiseizure treatment
US5198548A (en) *	1992-01-30	1993-03-30	Warner-Lambert Company	Process for the preparation of D(-) and L(+)-3,3-diphenylalanine and D(-) and L(+)-substituted 3,3-diphenylalanines and derivatives thereof

1993
- 1993-05-18 SG SG1996008718A patent/SG48288A1/en unknown
- 1993-05-18 EP EP93925173A patent/EP0641330B1/fr not_active Expired - Lifetime
- 1993-05-18 SK SK1395-94A patent/SK283281B6/sk not_active IP Right Cessation
- 1993-05-18 RU RU94046105/04A patent/RU94046105A/ru unknown
- 1993-05-18 HU HU9403310A patent/HU222339B1/hu active Protection Beyond IP Right Term
- 1993-05-18 DE DE1993630949 patent/DE122004000039I2/de active Active
- 1993-05-18 CZ CZ19942849A patent/CZ286106B6/cs not_active IP Right Cessation
- 1993-05-18 RU RU96124481A patent/RU2140901C1/ru active
- 1993-05-18 AU AU43794/93A patent/AU677008B2/en not_active Ceased
- 1993-05-18 NZ NZ253459A patent/NZ253459A/en not_active IP Right Cessation
- 1993-05-18 CA CA002134674A patent/CA2134674C/fr not_active Expired - Lifetime
- 1993-05-18 JP JP50380794A patent/JP3856816B2/ja not_active Expired - Lifetime
- 1993-05-18 DK DK93925173T patent/DK0641330T3/da active
- 1993-05-18 PT PT93925173T patent/PT641330E/pt unknown
- 1993-05-18 HU HU9702482A patent/HU222776B1/hu active IP Right Grant
- 1993-05-18 KR KR1019940704158A patent/KR950701625A/ko not_active Application Discontinuation
- 1993-05-18 AT AT93925173T patent/ATE207052T1/de active
- 1993-05-18 WO PCT/US1993/004680 patent/WO1993023383A1/fr active IP Right Grant
- 1993-05-18 ES ES93925173T patent/ES2165857T3/es not_active Expired - Lifetime
- 1993-05-18 DE DE69330949T patent/DE69330949T2/de not_active Expired - Lifetime
1994
- 1994-11-16 NO NO944370A patent/NO944370L/no unknown
- 1994-11-18 FI FI945426A patent/FI945426A0/fi not_active Application Discontinuation
1998
- 1998-11-17 HK HK98112078A patent/HK1011022A1/xx not_active IP Right Cessation
2004
- 2004-03-16 JP JP2004075406A patent/JP4297814B2/ja not_active Expired - Lifetime
- 2004-10-06 LU LU91112C patent/LU91112I2/fr unknown
- 2004-11-22 NL NL300164C patent/NL300164I2/nl unknown

Also Published As

Publication number	Publication date
FI945426A (fi)	1994-11-18
ES2165857T3 (es)	2002-04-01
KR950701625A (ko)	1995-04-28
AU4379493A (en)	1993-12-13
EP0641330A4 (fr)	1997-05-28
JP4297814B2 (ja)	2009-07-15
NL300164I1 (nl)	2005-01-03
SK139594A3 (en)	1995-05-10
HUT71522A (en)	1995-12-28
DK0641330T3 (da)	2001-12-03
SK283281B6 (sk)	2003-05-02
ATE207052T1 (de)	2001-11-15
NZ253459A (en)	1997-03-24
RU94046105A (ru)	1997-06-20
SG48288A1 (en)	1998-04-17
DE122004000039I2 (de)	2006-06-29
DE122004000039I1 (de)	2006-05-18
NL300164I2 (nl)	2005-02-01
FI945426A0 (fi)	1994-11-18
CA2134674A1 (fr)	1993-11-25
RU2140901C1 (ru)	1999-11-10
LU91112I2 (fr)	2004-12-06
CZ284994A3 (en)	1995-03-15
JP3856816B2 (ja)	2006-12-13
JP2004238398A (ja)	2004-08-26
CA2134674C (fr)	2004-12-21
HU9702482D0 (en)	1998-03-02
PT641330E (pt)	2002-03-28
HU9403310D0 (en)	1995-02-28
DE69330949T2 (de)	2002-04-04
HK1011022A1 (en)	1999-07-02
WO1993023383A1 (fr)	1993-11-25
HU222776B1 (hu)	2003-10-28
EP0641330A1 (fr)	1995-03-08
JPH07508288A (ja)	1995-09-14
HU222339B1 (hu)	2003-06-28
AU677008B2 (en)	1997-04-10
NO944370D0 (no)	1994-11-16
CZ286106B6 (cs)	2000-01-12
DE69330949D1 (de)	2001-11-22
EP0641330B1 (fr)	2001-10-17

Publication	Publication Date	Title
NO944370D0 (no)	1994-11-16	Gamma-aminosyre- og L-glutaminsyreanaloger for behandling av anfall
MX9102241A (es)	1994-01-31	Analogos de gaba y de acido l-glutamico para tratamiento contra ataques.
IL110216A (en)	2003-05-29	Valproic acid amide derivatives and pharmaceutical compositions containing them
PT91145A (pt)	1990-02-08	Processo para a sintese de amino-acidos opticamente activos
MX9302970A (es)	1994-05-31	Analogos de acido l-glutamico y gaba para tratamiento anti-ataque.
ATE186907T1 (de)	1999-12-15	Optisch aktives 1-phenylpyrrolidonderivat und dessen herstellung